Abstract 1169P
Background
Acral lentiginous melanoma (ALM), although overall a rare type of melanoma, is the most common form of the disease in a number of countries in Latin America, Africa, and Asia; it is associated with a poor prognosis and recurrence. In this study, we seek to gain a better understanding of the tumor-immune components of ALM and their relationship to transcriptional programs.
Methods
Tumour samples were collected from patients undergoing treatment at the National Cancer Institute of Mexico, and have been annotated with vast clinical information. We performed transcriptome sequencing through exome-capture bulk RNA-sequencing on 65 primary tumors from 64 Mexican patients, and did spatial protein profiling using a tissue microarray on 110 tumor segments from 45 patients. Samples were collected at the National Cancer Institute of Mexico and have been annotated with vast clinical information.
Results
We identified differentially expressed genes such as CXCL8, MMP1, and TERT in ulcerated lesions. RNA deconvolution showed a high abundance of cancer-associated fibroblasts (CAFs) and the absence of NK cells. Consensus clustering identified three ALM subgroups based on global gene expression. Integration of spatial protein information confirmed the high abundance of CAFs- associated markers and the absence of CD56. Fibronectin, SMA, and the cancer stem cell marker CD44 were markedly elevated. We investigated expression patterns within particular regions of interest and found that fibronectin, VISTA, SMA, IDO1, CD34, CD45, CD3, HLA-DR, and CD45RO were differentially expressed in non-tumor regions, while tumor ROIs expressed B7-H3, CD127, GAPDH, and Ki-67 significantly at higher levels. Comparisons between RNA and protein for 35 targets are being conducted.
Conclusions
So far, our analyses point to genes that could drive important prognostic characteristics. We confirmed that ALM is characterized by an immunosuppressive tumor microenvironment. The role of CAFs and the mechanisms affecting NK cells require further research. The present project will enhance our understanding of the TME components and the antitumor response in an understudied disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Carla Daniela Robles Espinoza.
Funding
CONACyT A3-S-31603, UNAM PAPIIT IN209422, Welcome Sanger Institute International Fellowship, Melanoma Research Alliance Pilot Award #825924, William Guy Forbeck Research Foundation.
Disclosure
D. Adams: Other, Institutional, Other, DJA is supported by AstraZeneca, OpenTargets and is a paid consultant for Microbiotica: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13